Cheers Ahjay,
It’s hard to believe GSK would miss out the multi billion dollars cancer immunotherapy atm..
The combined annual revenues for Opdivo & Keytruda are expecting to reach $10billion this year...
Perhaps it’s too late to develop a checkpoint inhibitor, to compete directly with Opdivo & Keytruda...
The logical course of action would be a cheap entry via our Efti... if GSK is keen to participate...
I am expecting a strong and steady trading week. Have a great new week.
Good luck yo all holders ...
Cheers Ahjay, It’s hard to believe GSK would miss out the multi...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $523.0M | |||
| Open | High | Low | Value | Volume |
| 44.0¢ | 44.5¢ | 43.0¢ | $908.9K | 2.081M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 46894 | 43.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.0¢ | 44593 | 3 |
View Market Depth
| Last trade - 16.10pm 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
44.0¢ |
Change
0.000 ( 0.09 %) |
||||
| Open | High | Low | Volume | ||
| 43.5¢ | 44.5¢ | 43.0¢ | 488852 | ||
| Last updated 15.59pm 30/05/2024 ? | |||||
| IMM (ASX) Chart |